title: [Status epilepticus in the elderly patients. A retrospective study of 63 in-patients].
abstract: BACKGROUND
  Status epilepticus is quite frequent in the elderly but rarely studied despite the poor functional prognosis and significant mortality.
  
  
  METHODS
  We retrospectively evaluated the clinical manifestations and electroencephalogram findings observed over a two-year period in 63 consecutive inpatients aged over 70 years presenting status epilepticus. The variables studied included age, sex, the number of concomitant chronic active diseases, previous neurological disorders, brain lesions on CT or MRI, the use and withdrawal of medications and outcome.
  
  
  RESULTS
  The incidence of status epilepticus was 1%; two-thirds in women and one-third in men. The mean age was 83 years. Complex partial status epilepticus was noted in 91% with predominant features of confusion (89%), impairment of consciousness (75%) or psychiatric symptoms (46%). Etiologies were often multifactorial and acute symptomatic. Etiology was metabolic in 60%, drug-induced in 51%, demential in 44%, cerebrovascular in 37%, infectious in 30% and other neurological disorders in 28% of the cases. Antiepileptic drugs used to treat status epilepticus were benzodiazepine (60%), often in association with lamotrigine (51%), valproate (46%) or phenytoin (25%). Maintenance of an antiepileptic drug was found in 70% of cases. Complications were loss of autonomy (86%), malnutrition (67%), infections (51%), dementia (30%), pressure sores (14%), and recurrent epilepsy (13%). Mortality was 32% of cases and it was higher in men.
  
  
  CONCLUSIONS
  These findings have shown some special features of status epilepticus among the elderly but other prospective studies are needed to confirm these results and to identify optimal management to decrease mortality, and improve the poor functional prognosis.
authors.affiliation: Département de médecine interne et de gériatrie, CHU Albert-Chenevier-Henri-Mondor, 40, rue de Mesly, 94000 Créteil, France.
authors.forename: G
authors.initials: G
authors.lastname: Darcel
authors.forename: P
authors.initials: P
authors.lastname: Verstichel
authors.forename: S
authors.initials: S
authors.lastname: Herbaud
authors.forename: E
authors.initials: E
authors.lastname: Taillandier-Heriche
authors.forename: E
authors.initials: E
authors.lastname: Paillaud
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000453:epidemiology; D000927:Anticonvulsants / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000453:epidemiology; D015897:Comorbidity / Q000639:trends; D003221:Confusion / Q000453:epidemiology; D003244:Consciousness Disorders / Q000453:epidemiology; D004569:Electroencephalography; D005260:Female; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D008019:Life Style; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000453:epidemiology; D011859:Radiography; D012189:Retrospective Studies; D012727:Sex Characteristics; D013226:Status Epilepticus / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology*
chemical_list: D000927:Anticonvulsants